Drozdov V N, Shikh E V, Astapovskii A A, Khalaidzheva K N, Solovieva S A, Dorogun O B
I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, 119991, Moscow, Russian Federation.
Vopr Pitan. 2023;92(4):92-103. doi: 10.33029/0042-8833-2023-92-4-92-103. Epub 2023 Jun 30.
Despite the fact that dietary supplements (DS) are not medicines, an increasing number of publications testify to the effectiveness of probiotics consumed with food in the complex treatment and prevention of a number of diseases of the gastrointestinal tract, including irritable bowel syndrome (IBS) and antibiotic-associated diarrhea (AAD). of the study was to evaluate the effectiveness of the complex probiotic in the relief of diarrheal syndrome associated with intestinal microbiota dysbiosis in patients with IBS with diarrhea and AAD. . The study included 54 patients (31 with IBS with diarrhea and 23 with idiopathic AAD) aged 18 to 50 years. All patients included in the study were prescribed 1 capsule (350 mg) of the DS Neobiotic Lactobalance® per day for 21 days. One capsule contains: bifidobacteria (Bifidobacterium longum CBT BG7, Bifidobacterium lactis CBT BL3 Bifidobacterium bifidum CBT BF3), lactobacilli (Lactobacillus acidophilus CBT LA1, Lactobacillus rhamnosus CBT LR5), lactic acid bacteria (Streptococcus thermophilus CBT ST3), fructooligosaccharides, vitamin C. The daily intake of bifidobacteria was 8.7×10 CFU, lactobacilli - 6.1×10 CFU, lactic acid bacteria 3.1×10 CFU and vitamin C - 12 mg. The severity of symptoms was assessed in points (from 0 to 7 points) using the GSRS questionnaire (Gastrointestinal Symptom Rating Scale). All patients underwent a microbiological analysis of feces with an assessment of the degree of dysbiosis before and after the administration of DS. . In patients with IBS with diarrhea, the assessment of the manifestations of diarrheal syndrome according to the GSRS questionnaire decreased statistically significantly from 17 to 6 points (2.9 times), abdominal pain - from 12 to 4 points (3.0 times) and dyspeptic syndrome - from 8 to 3 points (in 2.7 times). In patients with AAD, also according to the GSRS questionnaire, the manifestations of diarrheal syndrome decreased statistically significantly from 13 to 3 points (4.3 times), abdominal pain - from 4 to 1 points (4.0 times) and dyspepsia syndrome - from 5 to 2 points (in 2.5 times). Against the background of DS intake, according to the data of bacteriological examination of feces, intestinal microbiota normalized by day 21 due to an increase in the number of lacto- and bifidobacteria (p=<0.05). . The study showed that the DS Neobiotic Lactobalance® contributes to the normalization of the intestinal microbiota and reduces the severity of clinical manifestations (diarrheal disorders or manifestations of diarrhea) in IBS and idiopathic AAD.
尽管膳食补充剂(DS)并非药物,但越来越多的出版物证实,与食物一同摄入的益生菌在多种胃肠道疾病(包括肠易激综合征(IBS)和抗生素相关性腹泻(AAD))的综合治疗和预防中具有有效性。本研究的目的是评估复合益生菌对伴有腹泻的IBS患者以及AAD患者因肠道微生物群失调而导致的腹泻综合征的缓解效果。该研究纳入了54名年龄在18至50岁之间的患者(31名伴有腹泻的IBS患者和23名特发性AAD患者)。所有纳入研究的患者均被规定每天服用1粒(350毫克)DS Neobiotic Lactobalance®胶囊,持续21天。1粒胶囊包含:双歧杆菌(长双歧杆菌CBT BG7、乳酸双歧杆菌CBT BL3、两歧双歧杆菌CBT BF3)、乳杆菌(嗜酸乳杆菌CBT LA1、鼠李糖乳杆菌CBT LR5)、乳酸菌(嗜热链球菌CBT ST3)、低聚果糖、维生素C。双歧杆菌的每日摄入量为8.7×10 CFU,乳杆菌为6.1×10 CFU,乳酸菌为3.1×10 CFU,维生素C为12毫克。使用GSRS问卷(胃肠道症状评定量表)以分数(从0至7分)评估症状的严重程度。所有患者在服用DS前后均接受了粪便的微生物学分析,并评估了失调程度。在伴有腹泻的IBS患者中,根据GSRS问卷,腹泻综合征的表现从17分降至6分(降低了2.9倍),腹痛从12分降至4分(降低了3.0倍),消化不良综合征从8分降至3分(降低了2.7倍)。在AAD患者中,同样根据GSRS问卷,腹泻综合征的表现从13分降至3分(降低了4.3倍),腹痛从4分降至1分(降低了4.0倍),消化不良综合征从5分降至2分(降低了2.5倍)。在服用DS的背景下,根据粪便细菌学检查数据,由于乳酸杆菌和双歧杆菌数量增加(p<0.05),肠道微生物群在第21天时恢复正常。该研究表明,DS Neobiotic Lactobalance®有助于肠道微生物群的正常化,并降低IBS和特发性AAD中临床表现(腹泻性疾病或腹泻表现)的严重程度。